Workflow
Mixie Technologies, Inc. (OTC: PHCG) Secures Minority Ownership Stake in Mixie Realty LLC
Globenewswire· 2026-02-26 13:00
Transaction expands Mixie’s platform strategy into immersive real estate visualization and technology-enabled property management DENVER, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Mixie Technologies, Inc. (OTC: PHCG), formerly known as Pure Harvest Corporate Group, Inc. (“Mixie” or the “Company”) today announced that it has closed on the acquisition of a 25 percent minority ownership interest in Mixie Realty, LLC (“Mixie Realty”), a next-generation real estate visualization and property management platform. The tra ...
SAGA Metals Announces Expiry of Warrant Acceleration Program and Receipt of C$3,422,888 in Warrant Proceeds since January 1, 2026
Globenewswire· 2026-02-26 13:00
VANCOUVER, British Columbia, Feb. 26, 2026 (GLOBE NEWSWIRE) -- SAGA Metals Corp. ("SAGA" or the "Company") (TSXV: SAGA) (OTCQB: SAGMF) (FSE: 20H), a North American exploration company focused on critical mineral discoveries, is pleased to announce the successful completion and expiry of its Warrant Acceleration Program (the “Acceleration”) of outstanding common share purchase Warrants of the Company issued in connection with a financing that closed in two tranches on May 23 and July 31, 2025 (the “May Finan ...
Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026
Globenewswire· 2026-02-26 13:00
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company’s fourth quarter 2025 financial results on Thursday, March 5, 2026, before the open of the U.S. financial markets. About Aligos Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company found ...
Cannara Announces Graduation to the Toronto Stock Exchange
Globenewswire· 2026-02-26 13:00
MONTREAL, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“Cannara”, “the Company”, “us” or “we”) (TSXV: LOVE) (OTCQX: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade cannabis products at affordable prices with two mega facilities based in Québec spanning over 1,600,000 sq. ft., is pleased to announce that it has received final approval to graduate (the "Uplisting") from the TSX Venture Exchange to the Toronto Stock Exchange (the "TSX"). "Graduating to the TSX represents a sign ...
Yoolie Park joins Solésence, Inc. as Vice President of Brand Partnerships
Globenewswire· 2026-02-26 13:00
Park brings over 20 years of industry experience to expand innovation and drive brand partner growth ROMEOVILLE, Ill., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN) a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that it has appointed Yoolie Park as Vice President of Brand Partnerships. In this role, Park will lead strategic relationships with emerging and established beauty brands, expanding Solésence’s ability to delive ...
Birchtech Announces Pricing of $15 Million Public Offering and Uplisting to NYSE American Stock Exchange
Globenewswire· 2026-02-26 13:00
CORSICANA, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Birchtech Corp. (NYSE American: BCHT) (TSX: BCHT) (“Birchtech” or the “Company”), a leader in specialty activated carbon technologies for sustainable air and water treatment, today announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock at a public offering price of $2.40 per share, before deducting underwriting discounts and commissions and offering expenses, for aggregate gross proceeds of approximately $15.0 mill ...
Lifetime Brands Announces Fourth Quarter and Full Year 2025 Financial Results Release Date and Conference Call
Globenewswire· 2026-02-26 13:00
Core Insights - Lifetime Brands, Inc. will release its fourth quarter and full year 2025 financial results on March 12, 2026, before market open [1] - The company will host a conference call at 11:00 a.m. Eastern Time on the same day to discuss the results [1] - The CEO and CFO will participate in the 38th Annual ROTH Conference from March 22-24, 2026, in Laguna Niguel, CA, and will be available for meetings with investors [4] Company Overview - Lifetime Brands is a leading global designer, developer, and marketer of a wide range of branded consumer products used in the home [5] - The company markets products under well-known kitchenware brands such as Farberware®, KitchenAid®, and Sabatier®, as well as respected tableware and giftware brands like Mikasa® and Pfaltzgraff® [5] - Lifetime Brands also provides exclusive private label products to leading retailers worldwide [5]
The Board of Directors of Oma Savings Bank Plc commences a new plan period of the employee share savings plan
Globenewswire· 2026-02-26 13:00
OMA SAVINGS BANK, PLC STOCK EXCHANGE RELEASE 26 FEBRUARY 2026 AT 15.00 P.M. OTHER INFORMATION DISCLOSED TO THE RULES OF THE EXCHANGE The Board of Directors of Oma Savings Bank Plc commences a new plan period of the employee share savings plan PLAN PERIOD 2026-2029, EMPLOYEE SHARE SAVINGS PLAN The Board of Directors of Oma Savings Bank Plc (“Company” or “OmaSp”) has decided to continue the employee share savings plan (“ESSP”) established in February 2024. The details of the new plan period correspond to the ...
Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference
Globenewswire· 2026-02-26 13:00
Core Insights - Milestone Pharmaceuticals Inc. will present at the TD Cowen 46th Annual Health Care Conference from March 2-4, 2026 [1] - A live webcast of the presentation will be available on March 3 at 9:10 AM EST, with a replay accessible for approximately 90 days [2] Company Overview - Milestone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative cardiovascular medicines for individuals with specific heart conditions [3] - The company's lead product, CARDAMYST™ (etripamil) nasal spray, is an FDA-approved treatment for converting acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults [3] - Etripamil is also under development for treating symptomatic episodic attacks associated with atrial fibrillation with rapid ventricular response (AFib-RVR) [3]
authID Selected by Point of Sale Lender to Provide Fraud Prevention and Identity Assurance
Globenewswire· 2026-02-26 13:00
Core Insights - authID has been selected by a U.S. point-of-sale lending and payment financing platform to enhance its identity verification processes, addressing the rising threat of identity fraud in consumer retail financing [1][2] Industry Context - The selection of authID highlights the increasing demand for biometric identity assurance in the consumer finance sector as fintech platforms face challenges from organized fraud and account takeover attacks that traditional verification methods cannot effectively mitigate [2][4] - In 2024, total U.S. payments fraud losses reached $12.5 billion, with Buy Now Pay Later (BNPL) transactions accounting for 15% of all purchases, indicating a significant risk in this area [5] Company Solutions - To combat fraud, the lender will implement authID Proof™ for identity verification using government-issued IDs during onboarding and authID Verified™ for biometric authentication during account access and high-risk transactions [6] - The platform aims to detect and prevent duplicate and fraudulent applications at onboarding, secure accounts against takeover, and maintain a seamless experience for legitimate users [10] Competitive Advantage - authID's biometric identity verification offers a competitive edge in the commoditized point-of-sale lending market by replacing traditional risk scores and vulnerable authentication methods with deterministic biometric proof, enhancing fraud defenses and customer satisfaction [9] - The company's patented PrivacyKey™ architecture ensures compliance with privacy laws while providing an audit trail based on verified biometrics, further solidifying its market position [8][12] Market Potential - The deployment of authID's solutions is expected to address the high-growth, multi-billion dollar fintech market by verifying the identity of users with industry-leading biometric accuracy in under a second [8][11]